Navigation Links
Erectile Dysfunction Drugs Market to Sink to USD 3.4 Billion by 2019: Transparency Market Research
Date:9/24/2014

Albany, New York (PRWEB) September 24, 2014

The global erectile dysfunction drugs market was worth $4.3 billion in 2012. It is expected to decline at an aggregate rate of 4.5% between 2013 and 2019, which means the market will be valued at $3.4 billion in 2019.

All facts and figures have be provided through a research report titled “Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019”, published by Transparency Market Research.

To browse through the research report, or to view the ToC, please visit: http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html

The report showed that Viagra (sildenafil citrate) by Pfizer held 45% of the global erectile dysfunction drugs market in 2012. Its majority hold over the market is predicted to decline after patent exclusivity rights expire in 2013 in Europe and other countries. Cialis (tadalafil) held the second-largest market share with $1.9 billion in 2012. Its patent exclusivity will reportedly expire in 2017, supplementing the decline of the erectile dysfunction drugs market by 2019. The same is to be expected from Levitra/Staxyn (Vardenafil) by Bayer, whose patent exclusivity is set to expire in 2018. The report explains that once the patents expire, the market will be flooded with competitive generic drugs with similar chemical compositions, reducing the revenue generated by the major players in the market.

Factors that might improve the growth of the erectile dysfunction drugs market are the approval of the new promising drugs Zydena (udenafil) and Stendra/Spedra (avanafil) in mid 2014.

The report categorized the global erectile dysfunction market according to the product brands or pipeline analysis. By products, the report investigates Viagra, Cialis, Levitra/Staxyn, MUSE, Zydena, Mvix, and Helleva. By pipeline analysis, the report identifies Vitaros, Uprima, Gene therapy, Melanocortin Activators, and Topiglan.

For further inquiries, ask here: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1550

By geography, the research report identifies the regions of North America, Europe, Asia-Pacific, and Rest of the World. The North American region dominated the global erectile dysfunction drug market in revenue created. It is expected to maintain its dominance throughout the forecast period.

The key players explained in the report are Pfizer, GlaxoSmithKline, Bayer, Dong-A Pharmaceutical Corporation Limited, Eli Lilly And Company, Cristalia Produtos Quimicos Farmaceuticos Ltda., Vivus Incorporated, S.K. Chemicals Corporation Limited, Meda Pharmaceuticals, and Apricus Biosciences, Incorporated.

Erectile dysfunction is a male inability to generate and/or maintain penile erection, for the sake of a fully successful sexual intercourse. It primarily affects men above the age of 40. Typical causes of erectile dysfunction are diabetes and hypertension, along with a host of common habits attributed to a sedentary lifestyle, obesity, excessive consumption of alcohol, smoking, use of recreational drugs, and use of anti-depressants.

Contact:

Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA/Canada Toll Free: 866-552-3453
Email: sales(at)transparencymarketresearch(dot)com
Web: http://www.transparencymarketresearch.com/

Read the full story at http://www.prweb.com/releases/2014/09/prweb12196007.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Does cycling increase risk for erectile dysfunction, infertility, or prostate cancer?
2. All men with gout should be routinely screened for erectile dysfunction
3. Erectile dysfunction can be reversed without medication
4. What is the link between erectile dysfunction and heart disease?
5. Erectile Dysfunction Tied to Long-Term Narcotic Use in Men
6. Long-term use of prescription painkillers for back pain linked to erectile dysfunction in men
7. Most Men With Erectile Dysfunction Dont Seem to Get Treatment
8. Most men with erectile dysfunction remain untreated, say US scientists
9. Erectile Dysfunction Clinic Set to Open April 1st in Maryland
10. Common erectile dysfunction drug not helpful for heart failure patients, study finds
11. The Elator Announces it's Recognition from The Sinclair Institute for its Penile Support Device for Men Suffering from Erectile Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
Breaking Medicine Technology: